Protamine sulfate use during tibial bypass does not appear to increase thrombotic events or affect short-term graft patency.
John PhairJohn FutchkoEric B TrestmanMatthew CarnevalePatricia FriedmannHarshal ShuklaKaran GargIssam KoleilatPublished in: Vascular (2020)
Heparin reversal with protamine sulfate after tibial or peroneal bypass grafting is not associated with higher cardiovascular morbidity, bypass thrombosis, amputation, or mortality. Additionally, there was no statistically significant difference in post-operative bleeding or thrombosis complications for patients who did not receive protamine, although the findings are suggestive of a potential difference in a more adequately powered study. Our results suggest that protamine sulfate is safe for intraoperative use without increased risk of thrombotic complications or early tibial bypass graft failure.